Treatment-resistant Depression (TRD)
8
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Transcranial Photobiomodulation (tPBM) for Somatic Symptoms in Treatment-Resistant Depression
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Personalized DBS Targeting for Treating Depression
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults
Auditory MMN EEG in TRD in Response to Ketamine